| Literature DB >> 29403811 |
Vicky Manyanga1, Ehab Elkady1,2, Jos Hoogmartens1, Erwin Adams1.
Abstract
Tobramycin is one of the aminoglycoside antibiotics that lack a UV absorbing chromophore. However, the application of pulsed electrochemical detection (PED) has been used successfully for the analysis of this and similar antibiotics. This work describes an improved liquid chromatographic (LC) method combined with PED, which is able to separate much more impurities than before. Using a Discovery C-18 RP column (250 mm×4.6 mm i.d., 5 μm), isocratic elution was carried out with a mobile phase, containing sodium sulfate (35 g/L), sodium octanesulphonic acid (1 g/L), tetrahydrofuran (14 mL/L) and 0.2 M phosphate buffer pH 3.0 (50 mL/L). Using these experimental conditions, the limit of quantification (LOQ, S/N=10) was 5 ng. The linearity was examined in the range LOQ-60 μg/mL and the coefficient of determination was 0.998. The method also proved to be repeatable and the recovery was close to 100%. The influence of the different chromatographic parameters on the separation was investigated by means of an experimental design. The proposed method is useful in quality control of tobramycin drug substances and drug products.Entities:
Keywords: Aminoglycoside antibiotics; Liquid chromatography-Pulsed electrochemical detection; Tobramycin
Year: 2013 PMID: 29403811 PMCID: PMC5760981 DOI: 10.1016/j.jpha.2012.12.008
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Fig. 1Chemical structures of tobramycin and its major impurities (kanamycin B, nebramine and neamine).
Fig. 2Typical chromatogram obtained after analyzing a tobramycin bulk sample using the improved method (nA: nano Amperes). The known impurity peaks are 7=neamine, 9=nebramine and 15=kanamycin B. The remaining impurities are of unknown identity.
Chromatographic parameter settings applied in the factorial analysis, corresponding to low (−), central (0) and high (+) levels.
| Parameter | Low value (−) | Central value (0) | High value (+) |
|---|---|---|---|
| Temperature (°C) | 43 | 45 | 47 |
| THF (mL/L) | 13 | 14 | 15 |
| Sodium octanesulphonate (g/L) | 0.9 | 1 | 1.1 |
| Sodium sulfate (g/L) | 33 | 35 | 37 |
Fig. 3Regression coefficient plots obtained from the factorial analysis. Rs1=resolution between peak 5 and peak 6, Rs2=resolution between neamine and nebramine, Rs3=resolution between nebramine and peak 10, Rs4=resolution between peak 10 and peak 12 and Rs5=resolution between kanamycin B and tobramycin THF=volume of tetrahydrofuran, temp=column temperature, sos=amount of sodium octanesulphonate, ss=amount of sodium sulfate.
Fig. 4Response surface plot: the influence of temperature (temp) and tetrahydrofuran (THF) on the separation of kanamycin B and tobramycin (Rs5). The other parameters are kept at their central points.
Analysis of commercial tobramycin bulk samples (%).
| Impurity | RRT | Sample 1 | Sample 2 | Sample 3 | Sample 4 |
|---|---|---|---|---|---|
| Peak 1 (Unk 1) | 0.20 | <LOQ | 0.08 | 0.09 | 0.14 |
| Peak 2 (Unk 2) | 0.24 | ND | <LOQ | <LOQ | 0.06 |
| Peak 3 (Unk 3) | 0.27 | <LOQ | 0.07 | 0.05 | <LOQ |
| Peak 4 (Unk 4) | 0.31 | ND | ND | ND | ND |
| Peak 5 (Unk 5) | 0.33 | ND | ND | ND | ND |
| Peak 6 (Unk 6) | 0.38 | 0.07 | 0.24 | 0.19 | 0.18 |
| Peak 7 (Neamine) | 0.48 | 0.05 | 0.17 | 0.14 | ND |
| Peak 8 (Unk 7) | 0.53 | <LOQ | <LOQ | <LOQ | ND |
| Peak 9 (Nebramine) | 0.57 | 0.05 | 0.16 | 0.12 | 0.12 |
| Peak 10 (Unk 8) | 0.62 | 0.29 | 0.12 | 0.40 | 0.19 |
| Peak 11 (Unk 9) | 0.66 | ND | ND | ND | ND |
| Peak 12 (Unk 10) | 0.68 | 0.11 | 0.06 | 0.17 | 0.11 |
| Peak 13 (Unk 11) | 0.69 | ND | 0.05 | <LOQ | <LOQ |
| Peak 14 (Unk 12) | 0.80 | ND | ND | ND | <LOQ |
| Peak 15 (Kanamycin B) | 0.87 | 0.20 | 0.44 | 0.13 | <LOQ |
| Peak 16 (Unk 13) | 0.92 | ND | ND | ND | ND |
| Peak 17 (Unk 14) | 0.96 | <LOQ | <LOQ | 0.10 | <LOQ |
| Peak 18 (Unk 15) | 1.19 | 0.08 | <LOQ | <LOQ | <LOQ |
Peak numbering according to Fig. 2. Unk=unknown impurity, RRT=relative retention time of impurity (versus the main peak), ND=not detected,
Fig. 5Typical chromatograms obtained after analyzing (1) Tobrex® and (2) tobramycin CRS using the improved LC-PED method. Sample concentration was 0.05 mg/mL.